POPULARITY
11 episodes with genomic testing
5 episodes with genomic testing
5 episodes with genomic testing
5 episodes with genomic testing
5 episodes with genomic testing
5 episodes with genomic testing
5 episodes with genomic testing
4 episodes with genomic testing
3 episodes with genomic testing
4 episodes with genomic testing
3 episodes with genomic testing
3 episodes with genomic testing
2 episodes with genomic testing
4 episodes with genomic testing
5 episodes with genomic testing
4 episodes with genomic testing
2 episodes with genomic testing
3 episodes with genomic testing
Send us Fan MailWelcome to Episode 30 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.What does it really take to make cancer care smarter? In this episode of Experts on Point, host Rachael Babin is joined by Associate Professor Jenny Liu and patient advocate Beth Ivimey to explore how precision oncology is reshaping not only cancer treatment but the way clinical trials are designed and delivered. It's a conversation that we hope you will find inspiring - its about combining innovation with compassion—and its a reminder that some of the biggest advances in oncology may come not only from scientific breakthroughs, but from building systems that put patients at the centre of every decision. Drawing on both clinical expertise and lived experience, they discuss genomic testing, trial navigation, toxicity management, patient partnership and the challenges of ensuring the right patient reaches the right trial at the right time. Together, they reflect on why the future of cancer research depends as much on smarter systems and meaningful collaboration as it does on scientific innovation.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter, a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us
Northern Livestock Video Market Sale Results Feeder cattle sold incredibly well at the Early Summer sale hosted by Northern Livestock Video Market. Check out the full sale report HERE. Advanced Genomics & Analytics Through Jorgensen Land & Cattle Evaluate The Ideal Beef Evaluation powered by Zoetis delivers Genomic Enhanced Estimated Breeding Differences (GEPDs) for 15 traits to help identify your best replacement females. Visualize With industry leading herd management, data analytics, and genetic visualizations, AgBoost makes genetic decision making simple and herd management easy. Propagate As the nation's largest seedstock producer, Jorgensen Land & Cattle has an unmatched selection of AI and Herd Sires to ensure the bulls you use meet the needs of your herd. Featured Experts in the Cattle Industry Larry Gran - Jorgensen Land & Cattle https://jorgensenfarms.com/ Follow On Facebook: @JorLandCat Shaye Wanner – Host of Casual Cattle Conversation https://www.casualcattleconversations.com/ Follow on Facebook: @cattleconvos Contact Us with Questions or Concerns Have questions or feedback? Feel free to reach out via: Call/Text: 707-RANCH20 or 707-726-2420 Email: RanchItUpShow@gmail.com Follow us: Facebook/Instagram: @RanchItUpShow YouTube: Subscribe to Ranch It Up Channel: https://www.youtube.com/c/RanchItUp Catch all episodes of the Ranch It Up Podcast available on all major podcasting platforms. Discover the Heart of Rural America with Tigger & BEC Ranching, farming, and the Western lifestyle are at the heart of everything we do. Tigger & BEC bring you exclusive insights from the world of working ranches, cattle farming, and sustainable beef production. Learn more about Jeff 'Tigger' Erhardt & Rebecca Wanner (BEC) and their mission to promote the Western way of life at Tigger and BEC. https://tiggerandbec.com/ Industry References, Partners and Resources For additional information on industry trends, products, and services, check out these trusted resources: American Gelbvieh Association: https://gelbvieh.org/ EquineMarket.Com: https://www.equinemarket.com/ Imogene Ingredients: https://www.imogeneingredients.com/ Jorgensen Land & Cattle: https://jorgensenfarms.com/ LivestockMarket.Com: https://www.livestockmarket.com/ RanchChannel.Com: https://ranchchannel.com/ RFD-TV: https://www.rfdtv.com/ Rural Radio Network: https://www.ruralradio147.com/ Sire Buyer: https://www.sirebuyer.com/ Westway Feed Products: https://westwayfeed.com/ Wrangler: https://www.wrangler.com/
It's The Ranch It Up Radio Show! Join Jeff Tigger Erhardt, Rebecca Wanner AKA BEC and their crew as we hear how feeder cattle sold in the Corn Belt Classic from Superior Livestock. Why capture DNA and genomics on the commercial cowherd, we'll find out. Plus market recaps and lots more wrapped into this all-new episode of the Ranch It Up Radio Show. Corn Belt Classic From Superior Livestock Feeder cattle sell incredibly well at the Corn Belt Classic hosted by Superior Livestock Auction. Check out the full sale report HERE or head to Superior Livestock Auction Market Report Page. Advanced Genomics & Analytics Through Jorgensen Land & Cattle Evaluate The Ideal Beef Evaluation powered by Zoetis delivers Genomic Enhanced Estimated Breeding Differences (GEPDs) for 15 traits to help identify your best replacement females. Visualize With industry leading herd management, data analytics, and genetic visualizations, AgBoost makes genetic decision making simple and herd management easy. Propagate As the nation's largest seedstock producer, Jorgensen Land & Cattle has an unmatched selection of AI and Herd Sires to ensure the bulls you use meet the needs of your herd. Featured Experts in the Cattle Industry Larry Gran - Jorgensen Land & Cattle https://jorgensenfarms.com/ Follow On Facebook: @JorLandCat Shaye Wanner – Host of Casual Cattle Conversation https://www.casualcattleconversations.com/ Follow on Facebook: @cattleconvos Contact Us with Questions or Concerns Have questions or feedback? Feel free to reach out via: Call/Text: 707-RANCH20 or 707-726-2420 Email: RanchItUpShow@gmail.com Follow us: Facebook/Instagram: @RanchItUpShow YouTube: Subscribe to Ranch It Up Channel: https://www.youtube.com/c/RanchItUp Catch all episodes of the Ranch It Up Podcast available on all major podcasting platforms. Discover the Heart of Rural America with Tigger & BEC Ranching, farming, and the Western lifestyle are at the heart of everything we do. Tigger & BEC bring you exclusive insights from the world of working ranches, cattle farming, and sustainable beef production. Learn more about Jeff 'Tigger' Erhardt & Rebecca Wanner (BEC) and their mission to promote the Western way of life at Tigger and BEC. https://tiggerandbec.com/ Industry References, Partners and Resources For additional information on industry trends, products, and services, check out these trusted resources: American Gelbvieh Association: https://gelbvieh.org/ EquineMarket.Com: https://www.equinemarket.com/ Imogene Ingredients: https://www.imogeneingredients.com/ Jorgensen Land & Cattle: https://jorgensenfarms.com/#/?ranchchannel=view LivestockMarket.Com: https://www.livestockmarket.com/ RanchChannel.Com: https://ranchchannel.com/ RFD-TV: https://www.rfdtv.com/ Rural Radio Network: https://www.ruralradio147.com/ Sire Buyer: https://www.sirebuyer.com/ Westway Feed Products: https://westwayfeed.com/ Wrangler: https://www.wrangler.com/
As agriculture becomes increasingly data-driven, producers are relying on more technology platforms to manage their operations.
Expanding a dairy operation requires more than just adding cows. It takes a strategic, data-driven plan. In this episode, Craig Gerrits of Country Aire Farms shares how his team leveraged genomic testing with CLARIFIDE® Plus to grow their herd while maintaining performance. From precision breeding using the Dairy Wellness Profit Index® (DWP$®) to selecting for key wellness traits, Craig walks through how genomic insights shaped every step of their expansion. He also discusses how early access to genomic data and ongoing collaboration with Zoetis streamlined decision-making. Tune in to hear how a forward-thinking approach with genetic testing can help set your dairy up for long-term success. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.
The government launched a two-year pilot of a genomic testing programme, allowing samples to be analysed locally. Health Minister Simeon Brown says it will cut wait times and uncertainty for cancer patients. Cancer Society chief executive Nicola Coom spoke to Corin Dann.
Drs. Cytryn, Foote, and Thummalapalli discuss recent data on HER2 testing modalities and the prevalence of HER2 positivity across hepatobiliary, upper GI, and colorectal cancers, highlighting implications for precision medicine. The conversation reviews the latest clinical trial findings and the evolving landscape of HER2-targeted therapies, with insights into optimal treatment sequencing for various GI cancer subtypes.
In this episode of the ACRO Podcast, ACRO Committee Member Dr. Nevine Hanna is joined by radiation oncologist Dr. Christopher Lee to discuss how genomic testing is refining risk stratification for patients with intermediate risk prostate cancer. He shares insights on integrating genomic data with clinical factors to guide decisions around active surveillance, radiation therapy, and determining which patients may benefit from androgen deprivation therapy (ADT) post-radiation. The conversation highlights practical takeaways for clinicians focused on more personalized, evidence based prostate cancer care.This episode of the ACRO Podcast is sponsored by Myriad Oncology.
In this episode of Your Health University, Jamie sits down with Dr. Jimmie Williamson, Chief Behavioral Health Officer at Your Health, to break down why behavioral health belongs inside primary care—not outside it. Jimmie explains how telehealth lowered stigma, how mental health diagnoses (“F codes”) often correlate with frequent ER use, and why Your Health moved from intuition to data-driven referral models using tools like Power BI. They also map the full behavioral health ecosystem—from psych nurse practitioners to therapists to the psych pharmacist—and clarify when and how teams should refer patients for the right level of support. The takeaway is simple: earlier behavioral health intervention can improve lives, reduce hospital visits, and strengthen value-based care outcomes system-wide. www.YourHealth.Org
In this episode of the Casual Cattle Conversations podcast, Shaye discusses the importance and benefits of genomic testing for commercial heifers, a practice she uses on her ranch with her husband and father-in-law. Shaye explains the ease and process of taking tissue samples from the ear for DNA testing, the valuable data it provides, and how it helps in making informed decisions about heifer selection and bull selection, ultimately improving herd quality and productivity. She also shares personal insights into adapting to these advanced techniques on your own operation. Tune in wherever you listen to podcasts! Catch more conversations like this one and learn more at https://www.casualcattleconversations.com/ Learn more about Profit Foundations for Ranchers here: https://www.casualcattleconversations.com/profit-foundations-for-ranchers 00:00 Introduction to the Podcast 00:17 Personal Insights on Genomic Testing 05:23 The Process of Genomic Testing 07:58 Benefits and Challenges of Genomic Testing 16:39 Conclusion and Contact Information
Dr. Lisa Duhaime is a board-certified medical oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.
In this STtalks, Steve Jaeger of United Vision Dairy in Wisconsin and Logan Martin, STgenetics Strategic Account Manager discuss the dairy farm's management goals and how STgenetics programs and services assist in achieving them. Along with covering Vision+™ genomic testing, Chromosomal Mating®, breeding strategies and the integration of a Beef on Dairy breeding philosophy, they touch on the importance of community involvement and future goals for United Vision Dairy.00:00 Introduction and Guest Welcome00:36 Farm Overview and Mission01:25 Genomic Testing and Chromosomal Mating®03:38 Breeding Goals and Selection Criteria05:56 Beef on Dairy Program09:31 Community Involvement and Outreach11:11 Future Goals and Advice12:41 Conclusion and Farewell
In this STtalks, Perrin Hicks of Hicks-Jacobs Dairies in Australia joins us to discuss herd management goals, sustainability practices, and how STgenetics programs and services aid their dairy operation. Learn about the farm's background, their commitment to sustainability, and Perrin's insights into the role of genetics and the Eco$ indexes in sustainably feeding the world. Plus, hear about their recent achievements and awards, including their experience as the Global Impact Leader - Oceania at the Global Innovation Summit.00:00 Introduction and Guest Welcome00:31 Farm Background and Operations03:12 Sustainability Practices at Hicks-Jacobs Dairies04:51 Community Engagement and Outreach05:35 Genomic Testing and Herd Management07:46 Breeding Goals and Sire Selection11:56 Robotic Milking Systems13:23 Global Innovation Summit Experience15:47 Future Goals and Advice17:23 Conclusion and Farewell
In this STtalks, Micah Bakker and Joel Van Veldhuizen from Rock Bottom Dairy in Iowa, and Eric Zwiefelhofer with STgenetics join us to discuss their reproductive and genetic successes. They delve into the farm's reproductive programs, including their synchronization protocols, and discuss how STgenetics programs like Vision+75™ and Chromosomal Mating® aid in herd management and achieving the dairy's genetic goals. Discover how these practices have contributed to Rock Bottom Dairy's accolades.00:00 Introduction and Guest Welcome00:38 Farm Overview and Management02:09 Reproductive Success and Awards02:53 Reproductive Program Details08:35 Genetic Program and Goals10:02 Genomic Testing and Its Benefits13:30 Chromosomal Mating® Program16:37 Future Goals and Conclusion
This episode explores the grit, growth, and grace behind building a successful ranch from the ground up. Luke and Natalie share how they turned a shared dream into a working legacy—growing from a small commercial herd to a nationally recognized registered Angus operation known for elite genetics and a customer-first mindset.We dive into:The early years—from purchasing their first commercial cows to flushing embryos and selling top-tier bulls.The business evolution—including their first online bull sale in 2021 and the move to their first live auction in 2024, which featured the $150,000 high-selling LT Talent bull.Faith and family balance—how they juggle running a ranch, raising three kids (Tad, Jaks, and Rue), and staying grounded in what matters most.Natalie's journey from pharmacy to ag advocacy, building an online platform that reaches over 200,000 followers across Instagram, TikTok, and podcasting.Luke's focus on genetics, performance, and sustainability, emphasizing that profitability and maternal strength go hand-in-hand.Their vision for the future, from expanding their herd to mentoring the next generation of producers and continuing to grow the ranch's reputation for quality and integrity.Listeners will also get a behind-the-scenes look at how Kovarik Cattle Co uses AI, embryo transfer, and genomic testing to stay on the cutting edge, while keeping family and faith at the heart of every decision.
In this episode, Brad shares his fall updates from western Minnesota before diving into a detailed discussion on genomic testing in dairy herds. Drawing on his experiences from recent farm visits in South Dakota and ongoing University of Minnesota research projects, he explores how producers are using genomics and whether the investment pays off.Brad explains that while some herds use genomic testing solely to decide which animals to breed to beef, he believes the technology's value lies much deeper — in improving herd genetics, managing inbreeding, verifying parentage, and advancing traits like health, fertility, and production components. He outlines the major testing companies (Neogen, Zoetis, and Genetic Visions), their costs (around $37–$42 per animal), and the kinds of data producers can expect from each, including A2 status, horned/polled traits, and wellness indices.The episode also includes two case studies:A small grazing herd where genomic testing clarified breed composition, revealed unknown sires, and identified A2 status across mixed-breed animals.A university research herd exploring polled genetics and crossbred performance, where Brad questions how well current evaluations reflect the true genetic potential of crossbreds like Normande and Montbéliarde crosses.Brad closes by summarizing the practical ways to use genomic information — from strategic breeding and heifer selection to developing niche markets like A2 milk products. His key takeaway: genomic testing can be a powerful tool for herd improvement, but it's only worth the cost when used strategically rather than as a simple breeding filter.Listeners are encouraged to share feedback or questions via The Moos Room's contact page or University of Minnesota Extension channels.Questions, comments, scathing rebuttals? -> themoosroom@umn.edu or call 612-624-3610 and leave us a message!Linkedin -> The Moos RoomTwitter -> @UMNmoosroom and @UMNFarmSafetyFacebook -> @UMNDairyYouTube -> UMN Beef and Dairy and UMN Farm Safety and HealthInstagram -> @UMNWCROCDairyExtension WebsiteAgriAmerica Podcast Directory
Ever wished you could get breeding values on your commercial Merinos without having to record weights, dates or pedigrees?This week, we're launching neXtPredict, our brand new genomic tool that lets you go straight from DNA to breeding values with just a simple TSU sample.Developed in partnership with Weatherbys Scientific, neXtPredict provides base genomic breeding values, parentage, poll/horn testing and a flock profile for Merino breeders. It's powered by the MerinoSelect database and backed by MLA-funded research through AGBU and Sheep Genetics.To announce the launch this week on the podcast, Ferg chats with Tamarah Luxton, Territory Manager at Weatherbys Scientific. Tamarah shares the story of Weatherbys' journey from managing thoroughbred pedigrees in Ireland to providing cutting-edge genomic testing for livestock across Australia. neXtPredict has three service tiers, designed to suit everyone from large commercial breeders to data-driven operations wanting deeper insights.CORE gives you access to the neXtPredict Portal, where you can view gBVs, parentage, poll/horn, flock profiles and indexes, and filter or rank animals on standard industry indexes or generic neXtgen Agri indexes.PLUS includes everything in CORE, plus trait correlation analysis, the creation of custom indexes, and one-on-one support from the neXtgen Agri team.PRO adds long-term data storage, the ability to include non-genomic traits (like wool quality or dag scores), view multi-year data, and work directly with our consultants on testing strategies and optimisation.If you are interested in using neXtPredict, get in touch with us here at neXtgen Agri:info@nextgenagri.comOr with Weatherbys Scientific:tluxton@weatherbys.com.auHead Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE
Straight from the 2025 World Dairy Expo, we sit down with Paulo Carvalho, International Sales & Research Specialist at STgenetics. Paulo share with us the rapid growth and evolving trends in the European dairy market, as well as his vision for the future of this market on the continent.00:00 Introduction and Guest Welcome00:27 Guest Background and Role00:58 Growth and Trends in the European Dairy Market02:24 Swiss Dairy Market Insights03:04 Current Market Demands and Trends03:39 Changes in Dairy Farming Landscape04:32 Young Generation in Dairy Farming05:45 High Demand Sires and Genetics06:38 Beef on Dairy Market08:05 Genomic Testing and Chromosomal Mating®09:25 A2A2 Milk Market11:28 Future of STgenetics® in Europe11:51 Conclusion
BUFFALO, NY - July 29, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on July 25, 2025, titled “Comprehensive genomic profiling of over 10,000 advanced solid tumors.” In this study, led by Jean-Paul De La O from Exact Sciences Corporation, researchers analyzed data from over 10,000 solid tumor samples from patients with advanced cancer and found that more than 90 percent contained genetic changes that could guide treatment. This work demonstrates the growing impact of large-scale tumor DNA and RNA testing on patient care. The researchers retrospectively analyzed OncoExTra assay information for 31 types of cancer, including breast, colorectal, prostate, lung, and ovarian cancers. Their analysis revealed that nearly a third of patients had alterations associated with approved drugs for their specific cancer, while another third had changes linked to therapies approved for other cancers. These results show that detailed genetic profiling could expand treatment choices. “Biomarkers associated with on- or off-label FDA-approved therapies were detected in 29.2% and 28.0% of samples, respectively.” Another relevant discovery was that many important mutations occurred at very low levels, which are often missed by simpler tests. By using a broad and highly sensitive approach, the scientists were able to identify these rare mutations. They also reported that 7.5 percent of samples carried gene fusions, unusual genetic events that can drive cancer growth. Such findings can be critical in selecting therapies that specifically target these abnormalities. The study also highlighted the value of RNA sequencing in detecting fusion events that traditional DNA tests might miss. Prostate cancer and certain sarcomas showed particularly high rates of these fusion alterations. This type of information can refine cancer diagnosis and improve therapy planning. In addition, the researchers identified changes in several major cancer-related pathways, including those that control cell growth, DNA repair, and immune system response. Alterations in these pathways can point to newer treatment options, such as immunotherapy or drugs designed to block specific cell signals. Overall, this study shows that comprehensive genomic profiling can guide more personalized cancer care by identifying mutations, gene fusions, and other molecular patterns. Advanced testing methods like the OncoExTra assay reveal treatment opportunities even in advanced cancers, ensuring that subtle but important genetic changes are detected. DOI - https://doi.org/10.18632/oncotarget.28757 Correspondence to - Jean-Paul De La O - jdelao@exactsciences.com Video short - https://www.youtube.com/watch?v=awiRhDfiMTE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28757 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, solid tumors, comprehensive genomic profiling, matched therapy, gene fusions, limit of detection To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Accuracy. Profitability. Productivity. That's STgenetics Vision+™ genomic testing offering and in this episode of STtalks, Mena Schmitt, STgenetics® Genetic Services Specialist joins us to discuss the benefits and offering of genomic testing from STgenetics®. Mena explains how genomic testing can enhance on-farm profitability through informed breeding decisions and how it can be utilized to assist dairy producers in achieving their goals.00:00 Introduction and Guest Welcome00:29 Benefits of Genomic Testing01:27 STgenetics® Genomic Testing Options01:37 Vision+20™: The Basics02:35 Vision+50™: Advanced Testing03:11 Vision+75™: The Flagship Product04:31 Ensuring Accuracy and Profitability06:13 Genomic Testing as Precision Agriculture07:31 Differentiating Vision+™08:51 Getting Started with Genomic Testing09:52 Recent Additions to the Genomic Portfolio10:49 Conclusion and Contact Information
AUA2025: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice CME Available: https://auau.auanet.org/node/43029 At the conclusion of this activity, participants will be able to: 1. Describe the research that led to the approval of genomic testing for prostate cancer and the implementation of advanced imaging for prostate cancer 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation 3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer 4. Discern the different prognostic endpoints provided by various genomic tests 5. Recognize candidates for, and implications of, germline testing for prostate cancer. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Join us as we learn more about this fourth-generation farm, Thiele Dairy of Clearwater, Nebraska. Bill Thiele shares his family's journey into dairy farming and how they have scaled their existing farm site to a nearly 3,000-cow milking herd. Utilizing Ultraplus™ gender-sorted semen, Vision+™ genomic testing and elevating their level of genetics through the STgenetics® Legend™ Program have been a few areas that have enhanced the farm's productivity and longevity.00:00 Introduction to Thiele Dairy00:33 History and Evolution of Thiele Dairy04:25 Current Operations and Family Involvement09:27 Partnership with STgenetics®18:03 Genomic Testing and Genetic Improvements29:39 Crossbreeding Program and Beef Production35:20 Future Goals and Conclusion
From innovative transplant surgery to genome screenings, Dr. Joe Sirven explores the future of healing.
Do you know the best strategies for genomic testing in NSCLC? Credit available for this activity expires: 4/30/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002496?ecd=bdc_podcast_libsyn_mscpedu
In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Janice Walshe, Consultant Medical Oncologist at St Vincent's University Hospital, Dublin, Ireland. They explore the economic realities of cancer diagnostics, fertility preservation in patients with breast cancer, and the impact of international collaboration on the future of clinical trials. Timestamps: 00:00 – Introduction 03:25 – Economic disparities and oncology care in Ireland 07:20 – Neoadjuvant therapy for HER2-positive breast cancer 10:13 – Spotlight on invasive lobular carcinoma 12:36 – Fertility preservation in breast cancer 15:20 – Menopause after cancer 19:09 – The latest clinical trials in Ireland 21:50 – International trials and research projects 23:50 – Walshe's three wishes for healthcare
In this STtalks, we sit down with Adelyn Allen, STgenetics® Beef Operations Manager and Francine Campagnari, STgenetics® Senior Research and Development Manager, to learn more about STgenetics® Brahman division and the success they have recently experienced. In this discussion we learn about the American Brahman Breeders Association Performance Breeder of the Year award that STgenetics® received along with the role Vision+™ genomic testing will play within breeding strategies and the next generation of Brahman cattle. Tune in for insights into how these advancements are setting new standards in genetic excellence and sustainability.00:00 Welcome and Introductions00:41 STgenetics®' Brahman Division Award03:13 Genetic Offerings and Data Collection04:48 Brahman Spring Production Sale07:37 Vision+™ Genomic Testing09:37 Impact of Genomic Testing14:39 Final Thoughts and Wrap-Up
As we celebrate Easter, STgenetics® recalls its partnership with the Easter Bunny to provide more joy, sustainability and efficiency to the Bunny Business! Tune in as we unfold how STgenetics® tools and technology have helped the Easter Bunny produce higher quality Easter eggs while also reducing environmental impact, a truly egg-celent story!00:00 Introduction to Easter Celebration00:28 The Easter Bunny's Sustainable Business00:55 Genomic Testing for Efficient Egg Production01:10 EcoFeed® Suite and Environmental Benefits01:40 Donor Output Index and Enhanced Egg Production02:16 Conclusion and Easter Wishes
An interesting new study from the Geisinger health system in Pennsylvania examining if genomic screening in a large population increases the identification of disease risk prompted Raise the Line to re-release a previous episode about a textbook designed to help all medical providers understand the clinical applications of genomic testing. Genomics in the Clinic: A Practical Guide to Genetic Testing, Evaluation, and Counseling from Elsevier Science Direct dives into the use of this important tool in diagnosis and screening, indicating how individuals may respond to drug therapies, and more. “We really need to educate all healthcare providers about the practice of genetics because they're going to be involved directly or indirectly in genetic testing and conveying information about what the results mean to patients and their families,” explains co-author Dr. Ethylin Wang Jabs, enterprise chair of the Department of Clinical Genomics for Mayo Clinic. Jabs and her co-author, Dr. Antonie Kline, director of Clinical Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center, chose a format that makes heavy use of case studies to help readers get a better grasp on this complicated field and they also include chapters on direct-to-consumer testing and the ethical and social implications in genomic medicine. “Any kind of potentially predictive testing can have ethical issues related to it, including insurance coverage, testing for family members, protections for minors, and more,” says Dr. Kline. Join host Caleb Furnas for an illuminating episode on an area of discussion in medicine that's growing in importance as the use of genetic testing rapidly increases. Mentioned in this episode: Genomics in the Clinic: A Practical Guide If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast
Join us as we sit down with Full Circle Dairy of Lee, Florida to learn about their remarkable growth through strategic genetic strategies and their innovative herd management. Greg Watts, Eric Diepersloot and Phillip Watts join us to share about their genetic journey as well as their current expansion plans. Full Circle Dairy has utilized STgenetics® Legend™ Program to boost their genetic growth and through a deliberate mating plan have been able to achieve 150 NM$ interval jumps over the past three years. This growth is not only shown within the consistency and quality of their herd but through their production and reproduction milestones as well. With plans to expand from their internal genetics only, Full Circle Dairy has quite the story and goals to share on this STtalks episode!00:00 Introduction to Full Circle Dairy00:40 Meet the Team: Roles and Responsibilities01:46 Current Operations and Growth Plans03:06 Challenges and Adaptations03:34 Partnership with STgenetics®05:37 Transition to Gender Sorted Semen06:38 Nutritional Adjustments for Better Conception Rates11:27 Genomic Testing and the Legend™ Program20:07 Breeding Strategies and Expansion30:32 Future Goals and Reflections34:30 Conclusion and Farewell
We kick off 2025 on Raise the Line by sharing some good news for providers struggling to keep up with the growing number of applications for genomic testing: a new book from Elsevier Science Direct has been designed to arm you with the knowledge you need. Genomics in the Clinic: A Practical Guide to Genetic Testing, Evaluation, and Counselingdives into the use of this important tool in diagnosis and screening, indicating how individuals may respond to drug therapies, and more. “We really need to educate all healthcare providers about the practice of genetics because they're going to be involved directly or indirectly in genetic testing and conveying information about what the results mean to patients and their families,” explains co-author Dr. Ethylin Wang Jabs, enterprise chair of the Department of Clinical Genomics for Mayo Clinic. Jabs and her co-author, Dr. Antonie Kline, director of Clinical Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center, chose a format that makes heavy use of case studies to help readers get a better grasp on this complicated field and they also include chapters on direct-to-consumer testing and the ethical and social implications in genomic medicine. “Any kind of potentially predictive testing can have ethical issues related to it, including insurance coverage, testing for family members, protections for minors, and more,” says Dr. Kline. Join host Caleb Furnas for an illuminating episode on an area of discussion in medicine that's growing in importance as the use of genetic testing rapidly increases.Mentioned in this episode: Genomics in the Clinic: A Practical Guide
Dr. Evan Yu presents the new evidence-based guideline on genetic testing for metastatic prostate cancer. He discusses who should receive germline and somatic testing with next-generation sequencing technologies, what samples are preferred for testing, and the therapeutic & prognosistc impacts of genetic testing. Dr. Yu emphasizes the need for awareness and refers to areas of active investigation and future research to improve personalized therapies for patients with metastatic prostate cancer. Read the full guideline, “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline” at www.asco.org/genitourinary-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02608 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Evan Yu from the University of Washington and Fred Hutchinson Cancer Center, lead author on “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline”. Thank you for being here today, Dr. Yu. Dr. Evan Yu: Thanks for having me on. Brittany Harvey: Great. Then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the entire guideline, including Dr. Yu, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, Dr. Yu, to start us off on the content of this guideline, could you first provide an overview of both the purpose and scope of this guideline? Dr. Evan Yu: Yeah, absolutely. So I think the one key thing to recognize is that prostate cancer is the highest incidence of all cancers in males. Additionally, it's the second highest cause of mortality in males, and that's about 35,000 deaths in 2024. So with that being said and done, it's a disease where we need to do better. And part of that is recognizing that we now have many targeted therapies, precision medicine type of therapies, but unlike a lot of other cancers out there, prostate cancer patients are not always getting sequencing, next generation DNA sequencing, let's say, to identify both inherited and also spontaneously develop what we call somatic mutations in their tumor. And I suspect that's partially because other cancers like breast cancer, we're so used to- in the first line, you present the patient, you throw out their estrogen receptor status, progesterone receptor status, HER2, ER/PR HER2; in lung cancer it's EGFR, ALK, ROS1, etc. In things like prostate cancer, things like BRCA2 have major important patient treatment implications and potentially family counseling and downstream cascade testing implications. But it hasn't made their way into that first-line presentation yet. And for that reason, there are some studies out there that show that testing in the community may be as low as 15% of patients with metastatic prostate cancer. We want to bring awareness to that and hopefully increase testing down the road so that we can better help our patients with metastatic prostate cancer. Brittany Harvey: Absolutely. It's important to get these targeted therapies to the patients who can benefit most. Using that context, I'd like to next review the key recommendations of this guideline across the six clinical questions that the panel addressed. So, starting with: Who should receive germline testing with next generation sequencing technologies? Dr. Evan Yu: Yeah. We think that it's common enough that everyone with metastatic prostate cancer should receive germline genetic testing. And the reason for that is there have been studies that have looked at this and have shown that 12% of men with metastatic prostate cancer have some sort of inherited germline mutation in a gene, mostly DNA repair genes. But 12% have something that is inherited and that loved ones, first degree relatives, siblings, offspring might have also inherited. Now, most of these are in the DNA repair genes, but that being said and done, there's not only treatment implications for the patient, where there are newer drugs that that patient could get treated with, but other loved ones that might have inherited these gene mutations, that these things can cause other cancers as well - not just prostate cancer, but breast cancer, endometrial cancer, ovarian cancer, pancreatic cancer. So, it's very important to test, with as high of an incidence as 12%, to test, and if you identify it in a patient, it's our job to talk to the patient about it and talk to them about the pros and cons of family counseling and talking to their loved ones and potentially having their loved ones get tested. Because if they test positive, then their doctors may want to know and may screen them very, very aggressively and differently for a whole host of other cancers. And the whole idea is you find the cancer very early and cure the patients before the cancer really takes hold and has the ability to spread so we can save a lot of lives down the road. Brittany Harvey: Absolutely. This germline testing is important not just for the patient, but has wider implications for their families as well, as you mentioned. So then, beyond those recommendations for germline testing, which patients should receive somatic testing with next-generation sequencing technologies? Dr. Evan Yu: So let's talk a little bit about somatic testing. So germline again, as we know, is inherited. The patient inherited it in every single cell in their body, then it becomes very easy, many of these are cancer predispositions for them to lose the other allele and then to have biallelic loss and then develop the cancer. Now, somatic just means it spontaneously occurred. Certainly, it's not going to occur in every cell in the body, but you can get one hit, lose one allele and then lose the other allele. And if that gene is truly carcinogenic and leading to that cancer, then that can have implications potentially for treatment as well. So we recommend that all patients with metastatic prostate cancer also undergo somatic next-generation sequencing testing. We recognize that at this point in time it's only those with metastatic castration-resistant prostate cancer or hormone-resistant prostate cancer, which is a later disease state where there are drugs that may target those mutations, for instance, like PARP inhibitors, but that early identification for a patient population that's fit and that can benefit from these therapies makes sense so that you know it's in place already and you have your treatments outlined and mapped out for the future. So we recommend it for everybody - somatic testing also for everyone with metastatic prostate cancer. Brittany Harvey: Understood. And then when patients are receiving that somatic testing, what is recommended for somatic testing? Primary tumor archival tissue? Fresh metastatic biopsy tissue? Or circulating tumor DNA testing? Dr. Evan Yu: We recommend that in the initial setting when you're first diagnosed, that archival tissue samples are fine and preferred. But circulating tumor DNA is good when there's no accessible archival tissue, or if the archival tissue, let's say, is very old and it's been sitting around for a long time, or you can't get it anymore because it's many years back when maybe a patient had a prostate needle biopsy. So if it's not accessible, then we recommend ctDNA. We believe that is preferred and also that ctDNA is recommended in a situation where you can't easily biopsy a metastatic site. Sometimes it's just not in a safe area to go after. Sometimes it's just a small lesion. So in general, we recommend tissue when available, and when we think that the tissue sample will yield clean results, if not, then we recommend doing ctDNA at that point in time. Brittany Harvey: So you have described who should get germline and somatic genomic testing. But what are the therapeutic impacts of this germline or somatic testing for single gene genetic variants? Dr. Evan Yu: We pulled this panel together and we met like every single month for like 12 months straight, and part of it was to review the literature. And as part of this literature review, we were able to pull a whole bunch of different trials. I think there was like 1713 papers we identified in the literature search. Eventually, we narrowed it down because with ASCO, we want to present the data with the highest level evidence, level 1 evidence, randomized controlled prospective data. And after reviewing 1713 papers, we narrowed it down to 14 papers. With those 14 papers, if you look at it, there are a lot of things that we think may have implications for treatment or prognosis, but we didn't feel was the highest level of evidence that we could support. So the things that have the highest level of evidence that we can support are certain DNA repair gene alterations, especially BRCA2, and treatment with PARP inhibitors because there are many PARP inhibitor prospective trials that show progression-free survival benefit and even overall survival benefit. And so that's the type of study that achieved the level of evidence that we could include. So I would say BRCA1 and BRCA2 highest level of evidence and PARP inhibitor use also is included in that. Brittany Harvey: Understood. I appreciate you reviewing those therapeutic options. So then, the last clinical question, which you just touched on briefly, but what are the prognostic impacts of germline and/or somatic testing? Dr. Evan Yu: Whenever you do testing, especially if you use panel testing, you find a lot of information. There's a lot of different mutations and some of which are VUSs (variants of unknown significance) where we don't quite know what it means yet, but we can track that, especially if it's germline. But with somatic, we find lots of things that have implications, but maybe just not treatment implications. A perfect example is p53. p53 is one of the most common tumor suppressor gene mutations on all cancers, but in prostate cancer they can occur and they can usually occur late, although there can even be germline inherited p53 alterations. There's no treatment that targets p53 right now, but we know that if you have a p53 mutation that those patients may have more aggressive disease and that prognostic information is important to give to the patient. And I think it's important for future clinical trial design and direction. So we do not recommend making treatment recommendations or changes based on these prognostic only biomarkers at this point in time. But we do recommend that, based on this, we can design intensification trials for those patients who have these poor risk biomarkers and de-intensification trials for patients who may have a good risk biomarker. So for instance, SPOP is a gene where we think these patients may have better outcomes, they might respond better to certain hormonal therapies like abiraterone. I say might because the level of evidence isn't quite there. But what I would say is that these prognostic only biomarkers, we just don't think they cut the mustard yet to be able to make treatment decisions. But we do think that they can drive counseling for the patient and potential selection and trial design for the future to say, “Okay. This is a patient population that has a more aggressive cancer. We need to be more aggressive in treating these patients.” “This patient population might have a less aggressive cancer. Maybe we can de-intensify and say side effects and quality of life may be better for the patients.” Brittany Harvey: Definitely. It's important for thinking through how to personalize care for these patients. So then you've talked about this a little bit in talking through the recommendations, but could you expand on what is the importance of this guideline and how it will impact both clinicians and patients with metastatic prostate cancer? Dr. Evan Yu: Yeah, I think the number one thing is awareness. I think the data's out there and people that are in my field, they know this. But by evidence of the fact that it's not first-line presentation lingo that everyone's talking about things like BRCA status, it means it hasn't necessarily disseminated all the way through. So it's increasing awareness of the fact that both germline and somatic alterations can occur and that these may have impacts on the patient for their treatment and their prognosis, and basically to increase testing for the future. I really think that in the future, there'll be other reasons that we may want to serially even retest and we may find that there may be mutations that develop as mechanisms of resistance that might guide therapy down the road. So we need to get people to start doing this for everyone with metastatic prostate cancer, because someday we might be doing it not just once, but over and over again. Brittany Harvey. Absolutely. We hope this guideline reaches a wide audience and that these recommendations can be put into practice. Finally, you've talked about how not all the data in the field has yet risen to the level of evidence that made it into the guidelines. So what are the outstanding questions in future research areas for both germline and somatic genomic testing for metastatic prostate cancer? Dr. Evan Yu: It was in our discussion, but it clearly- it's not common enough for there to be randomized prospective trials that would reach that level of evidence to make it in this guideline recommendation. But we all know that for any solid tumor, you can get mismatched repair deficiency, microsatellite instability leading to hypermutation or high tumor mutational burden. And that happens in maybe 3 to 5% of patients with metastatic prostate cancer as well. There is evidence and data that these patients can potentially benefit from immunotherapies like pembrolizumab. But again, it's just not common enough for there to be those randomized prospective controlled trials out there. But we mention it because we know it's FDA-approved across all the tumor types, so we felt like we have to mention it because that's something that has treatment implications for the patient. But also, I alluded to this earlier, I think an area of active investigation is the tried and true number one driver of prostate cancer, which is androgen receptor. Testosterone binds to androgen receptors, stimulates it. That's how androgen deprivation therapy works. That's how abiraterone and the amides like enzalutamide, apalutamide, darolutamide, that's how they all work. But even beyond that, we're starting to identify that maybe 15%, 20% of patients with metastatic castration resistant prostate cancer have androgen receptor mutations. And there are newer classes of therapies like androgen receptor degraders like CYP11A1 antagonist that lead to complete adrenal annihilation of other steroid hormones that might promiscuously stimulate these androgen receptor mutants. These things develop as mechanisms of resistance, and in the future, we might want to serially test- and that's an active area of investigation in the future, to say you've been treated, let's say, with androgen deprivation therapy and abiraterone for years. There are certain mutations that might develop as a resistance mechanism. We might need to serially test somebody because you didn't have that mutation earlier on, but later in the disease course you might. And then there might be a new drug X out there that we would want to use. Again, we need the data, we need the randomized prospective controlled trials, but they're happening out there. And somewhere down the road we may rewrite this guideline and have a lot more recommendations to add to it. Brittany Harvey: Yes, we'll look forward to more research in this field to better provide targeted therapies for patients with metastatic prostate cancer across the treatment paradigm. And we'll look forward to report outs from those trials that you mentioned. So I want to thank you so much for your work to develop this guideline and thank you for your time today, Dr. Yu. Dr. Evan Yu: Thank you so much. It's wonderful to be here today. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Join us as we learn more about the 2024 MILK Business Leader in Technology Award winner, GenoSource! We sit down with Tim Rauen, GenoSource's CEO and Part-Owner to learn about the farm and the technologies he believes are pushing GenoSource forward and helping them achieve their goals! Technology is immersed within all that GenoSource does and Tim goes into details on what is used within GenoSource's infrastructure as well as on the genetic side of their business. 00:00 Introduction and Guest Welcome 00:39 Overview of GenoSource 01:19 Production and Facilities at GenoSource 02:11 Unique Technologies at GenoSource 02:55 Early Adoption of Genomic Testing and IVF 04:14 STgenetics®' Technologies and Infrastructure 07:24 IVF Program Scale and Goals 09:14 Achievements and Future Plans 12:24 Conclusion and Final Thoughts
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
In this episode, Dr. Bravo and Dr. Rogu speak with Dr. Molly O'Shea, a pediatrician and owner of a holistic family practice in Michigan. They discuss the emerging field of personalized medicine in Michigan and Dr. O'Shea's journey into pediatrics. Dr. O'Shea shares her experiences, detailing her innovative practice model, including home visits and a holistic approach. She also delves into the significance of genetic screening in early childhood and her work with rare diseases. The conversation covers pediatric care's challenges and potential future, touching on the importance of mental health, the microbiome, and the evolving role of primary care in pediatrics.This episode is sponsored by our friends at Freed.ai. Without their generous contribution, the show would not be possible. Dr. Rougu uses this product daily, and as he says, "It has changed my life. I don't work anymore." Please visit their website and support our sponsors. 00:00 Introduction and Setting the Scene00:09 Meet Dr. Molly O'Shea01:02 Dr. Molly's Journey to Pediatrics04:42 Family Influence and Childhood Challenges06:26 Resilience and Overcoming Adversity13:20 Innovative Pediatric Practice24:48 Personalized Medicine and Rare Diseases34:00 Advocacy and Future Projects37:29 The Illusion of Deleting Social Media Data38:10 Understanding Genetic Conditions: Monogenic vs Polygenic44:25 Penetrance and Its Role in Genetic Conditions51:47 Challenges in Pediatric Genetic Screening56:06 Future of Pediatrics: Personalized Medicine and Microbiome01:00:20 The Financial Struggles in Pediatric Care01:06:57 The Role of Extenders in Pediatric Practice01:12:49 Concluding Thoughts and Future MeetingsSupport the show
When it comes to management changes, the path from asking “Does it make sense?” to achieving more success is rarely clear. But when a dairy navigates that journey, the rewards can be plentiful — and can lead to additional opportunities to refine and improve productivity. Beth Dahl joins us from Mountain View Dairy in Delta, Utah. Beth has firsthand experience using genomic testing with CLARIFIDE® Plus, having stood where many of you are today, asking herself, “Does this make sense?” Ultimately, Beth, alongside Mountain View Dairy, jumped into the implementation and application of genomic testing with two feet and hasn't looked back.
We must remember that the people working long hours to achieve a dairy's production goals are still just people. And they invest more than just labor into an operation's success. Beth Dahl of Mountain View Dairy in Delta, Utah, has a lot to say about how her team finally solved a yearslong problem with bloating in calves thanks to some help from genomic testing with CLARIFIDE® Plus.
Tumor profiling or genomic testing can give us information about the genes in a person's cancer cells and can help guide doctors to the best possible treatment plan by predicting the risk of recurrence, or when breast cancer returns after initial treatment. If a low risk of recurrence is shown, people with breast cancer and their doctors can choose to pursue a less aggressive treatment plan with confidence. Here today to empower us with information about the power of genomics and to give further insight into how it can positively affect treatment decisions is Medical Oncologist, specializing in Breast Cancer and Cancer Genomics, and Chief Medical Officer at Agendia, Dr. William Audeh.
Join us for an enlightening journey as we sit down with Stewart Staudinger, who shares his remarkable transition from an aeronautical engineer and Royal Air Force pilot to a full-time bison rancher in central Alberta. Stewart recounts his early years on a purebred Simmental cattle ranch and his eventual return to the family ranch, inspired by his father's shift from cattle to bison. Listen in as Stewart provides a vivid picture of the unique management aspects of bison, their wild nature, and the fascinating dynamics of herd behavior.We also explore the intricacies of bison genetics and breeding strategies, highlighting the differences between plains and wood bison subspecies and the advancements in genomic testing. Stewart discusses the practical aspects of handling and weaning calves, sharing the learning curve new ranchers face. Our conversation emphasizes the importance of these genetic discoveries for herd registry management and classification, providing invaluable insights for those interested in bison ranching.In the latter part of our discussion, we shift focus to the operational aspects of running a diverse meat business and the challenges of grazing management. Stewart shares his experiences with marketing strategies, feeding regimens, and the significant infrastructure improvements he's implemented to support sustainable grazing practices. From innovative fencing techniques using sucker rod to enhancing soil health through regenerative agriculture, Stewart's journey offers a wealth of knowledge for anyone interested in sustainable and profitable ranching. Tune in to gain a comprehensive understanding of the multifaceted world of regenerative bison ranching.Links Mentioned in the Episode:MFL Bison Ranch Visit our Sponsors:Noble Research InstituteKencove Farm Fence
Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice CME Available: https://auau.auanet.org/node/41033 At the conclusion of this activity, participants will be able to: 1. Identify the research that led to the approval of genomic cancer for prostate cancer and the implementation of advanced imaging for prostate cancer. 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation. 3. State the National Comprehensive Cancer Network Guidelines for genomic testing and advanced imaging for prostate cancer. 4. Discern the different prognostic end points provided by various genomic tests. 5. Recognize candidates for, and implications of, germline testing for prostate cancer. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
We're digging into genetic testing to improve pregnancy success and prevent or decrease the risk of pregnancy loss. At Fab Fertile, we've been offering genetic/genomic testing as part of our method for years. This genetic testing is very different from the testing you would receive from your conventional doctor. Our genetic testing looks at specific gene variants and makes specific diet/lifestyle recommendations and supplements that can support your genes. Your genes are not your destiny, and there are targeted steps you can take to optimize your fertility and pregnancy success. I'm excited to announce that we have an even better genetic test that helps improve pregnancy outcomes. Designed to improve preconception health, birth outcomes, recurrent miscarriage, gestational diabetes and preeclampsia, the GrowBaby test identifies pathways that need support and helps us determine a customized plan based on your DNA. I'm excited to welcome Helen Gautschi to the podcast. Helen is a registered dietician (SA) and holds a Bachelor of Science in Dietetics (Honours) degree from Stellenbosch University in South Africa. She is also the Head of Research and Development and Education at DNAlife, which offers the GrowBaby genetic test. In this episode, you'll learn: 1) How the GrowBaby test can improve birth outcomes and decrease the risk for preeclampsia and gestational hypertension and diabetes and miscarriage or pregnancy loss 2) How to support each pathway with specific diet/lifestyle and supplement recommendations 3) Why the preconception period is critical and specific steps you can take to improve healthy birth outcomes --- RESOURCES: Fab Fertile Method https://www.fabfertile.com/what-we-do/ Ultimate Guide to Getting Pregnant This Year If You Have Low AMH/High FSH - https://fabfertile.clickfunnels.com/optinvbzjfsii Ultimate Diet for Egg and Sperm Health - https://fabfertile.com/blogs/podcasts/the-ultimate-diet-for-egg-and-sperm-health Want to Get Pregnant This Year - https://fabfertile.com/blogs/podcasts/want-to-get-pregnant-this-year Top Fertility Supplements You Need To Get Pregnant This Year - Access your free guide here at www.suppguideffl.com --- Where should I start to optimize pregnancy success? Get started with the Fertility Preparation Bundle (US residents only) here https://fabfertile.com/products/fertility-preparation-bundle and use code LAUNCH15 to save 15%. --- Get your free copy of our Spring Fertility Recipe Guide (includes 5-day meal plan/grocery shopping list, all free from the TOP allergens) at https://www.fertilitydietfreebie.com/. --- Join my FREE Facebook group and get my training on HOW to improve pregnancy success with your own eggs. https://www.facebook.com/groups/451444518397946 --- Check out https://www.fabfertile.com/blogs/podcasts/why-genomic-testing-can-help-with-recurrent-pregnancy-loss-birth-outcomes-and-preconception-health/ --- Please note when promoting a product, we only select products that either Sarah Clark or her team has tried and believe are beneficial for someone who is TTC. We may receive a small commission.
In this episode, host Shikha Jain, MD, speaks with Barnaby Balmforth, PhD, about the evolution of genomics in cancer care, the impact of personalized care tools and more. • Welcome to another exciting episode of Oncology Overdrive :58 • About Balmforth 1:12 • The interview 3:01 • How did you get to where you are today? What drove you to become a leader in this space? 3:45 • What is genomics, and why is genomic analysis important in cancer care? 7:18 • Jain and Balmforth on the evolution of technology and challenges facing genomics and diagnostic testing to achieve personalized care for individual patients. 11:59 • In addition to time, can you speak on the challenge of access for this type of technology? 13:20 • How have you been able to implement “next day” test results and reports of your technology? 17:50 • Jain and Balmforth on how Biofidelity's technology can transform the delivery of care, as well as its psychological and mental impact. 19:06 • What's coming down the line for you and Biofidelity? 20:56 • What are your thoughts for when you expand beyond thoracic oncology? What are your long-term visions for other disease sites? 24:19 • Do you have any thoughts on AI and how it may influence genomics in cancer care? 25:51 • If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:37 • How to contact Balmforth 30:37 • Thanks for listening 31:10 Barnaby Balmforth, PhD, is co-founder and CEO of Biofidelity. Barnaby has more than 15 years' experience in the leadership of multidisciplinary technology development. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Balmforth can be reached via the Biofidelity website. Disclosures: Jain reports no relevant financial disclosures. Balmforth reports he is an employee of Biofidelity and owns shares in the company.
Season 7 || Episode 11 Have you heard these myths about genomic testing in cattle? 1. Genomic testing is only for seedstock producers. 2. Genomic testing is too complex and time-consuming for commercial producers. 3. Genomic testing doesn't provide practical benefits for commercial operations. Nick Hammett and host Shaye Wanner bust these myths and dive into practical ways you can use genomics as a commercial cow-calf producer. In this episode, you will be able to: Uncover the potential of genomic testing to improve your cattle breeding strategies and boost profitability. Harness the power of genomic data to make more informed and effective mating decisions for your cattle operation. Discover what traits are analyzed in the Igenity Beef Test and how to use these when selecting replacement heifers Learn how genomic data helps build relationships with cattle buyers Cultivate patience as a key virtue in the genetic selection process to achieve long-term success in your cattle breeding endeavors. Learn more about Igenity Beef https://www.neogen.com/igenity-beef My special guest is Nick Hammett Nick Hammett, currently serving as a key accounts manager at Neogen, brings substantial expertise in the beef industry. With a background that includes working for breed associations, a vertically integrated beef company, and a large commercial cow-calf operation, Nick has acquired a comprehensive understanding of the industry. His role involves assisting commercial cattle producers in making well-informed breeding decisions and improving the productivity of their operations. Nick's proficiency in genomic testing and its practical applications for commercial producers positions him as a knowledgeable authority for anyone seeking to enhance their breeding strategies and bolster profitability within the beef industry. The key moments in this episode are: 00:00:01 - Introduction to casual cattle conversations 00:01:04 - Benefits of genomic testing 00:07:37 - Value of genomics for commercial producers 00:10:38 - Future of genomic information in the industry 00:12:07 - Leveraging genomic information for bull decisions 00:13:53 - Understanding Genomic Scores 00:15:03 - Importance of Genomic Scores 00:16:30 - Database Comparison and Selection Decisions 00:18:07 - Sample Collection and Process 00:19:52 - Using Indexes for Decision-Making Links: Full Show Notes: https://www.casualcattleconversations.com/casual-cattle-conversations-podcast-shownotes Free Weekly Resources: https://www.casualcattleconversations.com/ranching-resources • The easiest way to create a new revenue stream for your ranch is with LandTrust. Learn more here! www.landtrust.com/a/cattleconvos Take Your Ranch to the Next Level Once a month Shaye hosts Q&A calls between cattle producers and beef industry leaders to help ranchers find answers to their questions and improve their bottom lines. The best part is you get expert insight from the comfort of your own ranch and get to ask any question you want relating to the topic! Learn More About RancherMinds: https://www.casualcattleconversations.com/ranchermind-events Connect with me on Social Media Facebook - https://www.facebook.com/cattleconvos Instagram - https://www.instagram.com/cattleconvos/ Podcast Coaching Do you have an existing podcast or want to start a new one but don't know where to start? Connect with Shaye and she will lay out everything you need to know to get you started on the right foot. Find podcast resources and coaching opportunities here! https://www.casualcattleconversations.com/podcast-coaching
In this episode, Dr. Edward Schaeffer, chair of urology at Feinberg School of Medicine, discusses precision medicine in prostate cancer with Dr. Aditya Bagrodia. First, Dr. Schaeffer introduces the importance of using a defined screening strategy for prostate cancer that includes analyzing a patient's genomic and germline risk. Then, he summarizes existing and new diagnostic tools for prostate cancer. Additionally, Dr. Schaeffer discusses genomic testing and PSMA testing and explains how he applies them to individual patient cases depending on their cancer stage and grade. Finally, the doctors highlight the ability of future tools, like PET PSMA scans, to advance precision medicine. --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: https://earnc.me/3XO8iL --- SHOW NOTES 00:00 - Introduction 10:32 - Precision Medicine and Prostate Cancer 16:17 - Screening and Diagnosis of Prostate Cancer 29:41 - Personalizing Surveillance and Disease Management 33:11 - The Role of Genomic Testing in Prostate Cancer 45:00 - The Use of PET PSMA Scans in Prostate Cancer Staging 48:08 - The Future of Precision Medicine in Prostate Cancer
View the Show Notes For This EpisodeGet Free Weekly Health Tips from Dr. HymanSign Up for Dr. Hyman's Weekly Longevity JournalGet Ad-free Episodes & Dr. Hyman+ Audio ExclusivesDr. Sharon Hausman-Cohen is the Chief Medical Officer and co-founder of IntellxxDNA and has been in the field of integrative medicine for over 25 years. She is the co-author of many publications and a textbook chapter on using genomics to improve outcomes in cognitive decline and autism.This episode is brought to you by Rupa Health, Fatty15, BiOptimizers, and ARMRA.Streamline your lab orders with Rupa Health. Access more than 3,000 specialty lab tests and register for a FREE live demo at RupaHealth.com.Fatty15 contains pure, award-winning C15:0 in a bioavailable form. Get an exclusive 10% off a 90-day starter kit subscription. Just visit Fatty15.com and use code DRHYMAN10 to get started.Tackle an overlooked root cause of stress with Magnesium Breakthrough. Visit bioptimizers.com/hyman and use code HYMAN10 to save 10% and receive free gifts with your purchase.Save 15% on your first order of ARMRA Colostrum and unlock the power of 400+ functional nutrients. Just visit TryARMRA.com/Mark or use code MARK.In this episode we discuss (audio version / Apple Subscriber version):What are genes and what do they do? (6:37 / 4:33)Genetic predisposition does not mean predestined (9:22 / 7:18)The difference between genetics vs genomics (13:10 / 11:06)Polygenic risk scoring for chronic disease (18:18 / 16:14)Dementia risk and treatment (33:59 / 29:24)Mental and cognitive health issues in children (46:00 / 41:25)The similarities between Autism and Alzheimer's patients (49:49 / 45:14)My genomic test results, specifically related to detoxification and osteoporosis (52:21 / 47:45)Genetic vs genomic testing (1:06:29 / 1:01:54)Learn more at IntellxxDNA.com. Hosted on Acast. See acast.com/privacy for more information.
© 2020-2026 Ivy Podcast Discovery LLC
